Laurent Godinas, Fabienne Dobbels, Leni Hulst, Ive Verbeeck, Ines De Coninck, Pieter Berrevoets, Veronique Schaevers, Jonas Yserbyt, Lieven J Dupont, Stijn E Verleden, Bart M Vanaudenaerde, Laurens J Ceulemans, Dirk E Van Raemdonck, Arne Neyrinck, Geert M Verleden, Robin Vos
BACKGROUND: Lung transplantation (LTx) requires a calcineurin inhibitor-based immunosuppressive regimen. A once daily (QD) tacrolimus regimen was developed to increase medication adherence. However, data concerning its safety and efficacy in LTx are lacking. METHODS: In this prospective study, stable LTx patients were consecutively converted from twice daily (BID) tacrolimus to QD tacrolimus on a 1 mg:1 mg basis. Trough level (Cmin ), renal function, cholesterol, fasting glucose, potassium and lung function were monitored six months before and up to one year after conversion...
June 2021: Journal of Heart and Lung Transplantation